biotech · Bladder Cancer · Non Muscle Invasive Bladder Cancer · CGON
CG Oncology
CG Oncology is a biotech organization headquartered in Dallas, USA. It trades on NYSE under ticker CGON. Primary therapeutic focus areas include Bladder Cancer, Non Muscle Invasive Bladder Cancer, Transitional Cell Carci
Dallas, USA HQ
2010 Founded
187 Employees
Public company Type
CGON · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dallas, USA
- Founded
- 2010
- Employees
- 187
- Programs
- 8
- Drugs
- 1
- Patents
- 5
Cretostimogene Grenadenorepvec
Phase 3 · mab · Non Muscle Invasive Bladder Cancer
Cretostimogene Grenadenorepvec for Non Muscle Invasive Bladder Cancer is a Phase 3 program (mab) at CG Oncology with 2 ClinicalTrials.gov record(s).
Internal code CG3002S
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CG Oncology
- Phase
- Phase 3
- Modality
- mab
- Indication
- Non Muscle Invasive Bladder Cancer
- Status
- active
- Trials
- 2